Geron logo

Geron share price today

(GERN)

Geron share price is $2.98 & ₹257.81 as on 14 Jan 2025, 20.06 hrs IST

$2.98

-0.19

(-5.99%)

Market is closed - opens 8 PM, 14 Jan 2025

View live Geron share price in Dollar and Rupees. Guide to invest in Geron stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Geron, along with analyst recommendations, forecasts, and comprehensive financials.

Geron share price movements

  • Today's Low: $2.80
    Today's High: $3.05

    Day's Volatility :8.2%

  • 52 Weeks Low: $1.64
    52 Weeks High: $5.34

    52 Weeks Volatility :69.29%

Geron Returns

PeriodGeron CorporationSector (Health Care)Index (Russel 2000)
3 Months
-28.88%
-8.6%
0.0%
6 Months
-40.28%
-4.6%
0.0%
1 Year
51.27%
0.7%
0.0%
3 Years
170.91%
5.5%
-18.2%

Geron Key Statistics

in dollars & INR

Previous Close
$2.98
Open
$3.1
Today's High
$3.05
Today's Low
$2.8
Market Capitalization
$1.9B
Today's Volume
$22.5M
52 Week High
$5.34
52 Week Low
$1.64
Revenue TTM
$29.5M
EBITDA
$-207.5M
Earnings Per Share (EPS)
$-0.3
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-69.03%

How to invest in Geron from India?

It is very easy for Indian residents to invest directly in Geron from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Geron stock in both Indian Rupees (INR) and US Dollars (USD). Search for Geron or GERN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Geron or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Geron shares which would translate to 0.290 fractional shares of Geron as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Geron, in just a few clicks!

Returns in Geron for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Geron investment value today

Current value as on today

₹1,55,651

Returns

₹55,651

(+55.65%)

Returns from Geron Stock

₹51,269 (+51.27%)

Dollar Returns

₹4,382 (+4.38%)

Indian investors sentiment towards Geron

45.65%

Period: Oct 15, 2024 to Jan 13, 2025. Change in 30 Days versus previous period

Investment in Geron from India has grown in the last 30 days as on Jan 14, 2025. 45.65% more purchase transactions for Geron in the last 30 days versus the previous period.

-8%

Period: Oct 15, 2024 to Jan 13, 2025. Change in 30 Days versus previous period

Search volume for Geron on INDmoney from India has reduced in the last 30 days as on Jan 14, 2025. -8% less investors are searching Geron in the last 30 days versus the previous period.

Global Institutional Holdings in Geron

  • BlackRock Inc

    8.05%

  • RTW INVESTMENTS, LLC

    7.30%

  • Vanguard Group Inc

    5.37%

  • RA Capital Management, LLC

    5.34%

  • State Street Corp

    4.79%

  • Adage Capital Partners Gp LLC

    4.78%

Analyst Recommendation on Geron

Buy

    84%Buy

    15%Hold

    0%Sell

Based on 13 Wall street analysts offering stock ratings for Geron(by analysts ranked 0 to 5 stars)

Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
2
1
1
Sell
0
0
0

Analyst Forecast on Geron

What analysts predicted

Upside of 155.41%

Target:

$7.61

Current:

$2.98

Insights on Geron

  • Price Movement

    In the last 1 month, GERN stock has moved down by -22.8%
  • Increasing Revenue

    Revenue is up for the last 4 quarters, 23.0K → 28.27M (in $), with an average increase of 85.0% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -67.38M → -26.44M (in $), with an average increase of 154.8% per quarter

Geron Financials in INR & Dollars

FY18Y/Y Change
Revenue
$1.1M
↑ 0.09%
Net Income
$-27.0M
↓ 3.22%
Net Profit Margin
-2.5K%
↑ 86.79%
FY19Y/Y Change
Revenue
$460.0K
↓ 56.85%
Net Income
$-63.6M
↑ 135.23%
Net Profit Margin
-13.8K%
↓ 11281.0%
FY20Y/Y Change
Revenue
$253.0K
↓ 45.0%
Net Income
$-75.6M
↑ 18.98%
Net Profit Margin
-29.9K%
↓ 16069.95%
FY21Y/Y Change
Revenue
$1.4M
↑ 450.59%
Net Income
$-121.0M
↑ 59.97%
Net Profit Margin
-8.7K%
↑ 21202.54%
FY22Y/Y Change
Revenue
$596.0K
↓ 57.21%
Net Income
$-141.0M
↑ 16.6%
Net Profit Margin
-23.7K%
↓ 14980.42%
FY23Y/Y Change
Revenue
$237.0K
↓ 60.23%
Net Income
$-184.1M
↑ 30.56%
Net Profit Margin
-77.7K%
↓ 54027.46%
Q2 FY23Q/Q Change
Revenue
$29.0K
↑ 38.1%
Net Income
$-49.2M
↑ 29.29%
Net Profit Margin
-169.7K%
↑ 11556.48%
Q3 FY23Q/Q Change
Revenue
$164.0K
↑ 465.52%
Net Income
$-44.8M
↓ 8.98%
Net Profit Margin
-27.3K%
↑ 142428.16%
Q4 FY23Q/Q Change
Revenue
$23.0K
↓ 85.98%
Net Income
$-52.0M
↑ 16.0%
Net Profit Margin
-226.0K%
↓ 198653.79%
Q1 FY24Q/Q Change
Revenue
$304.0K
↑ 1221.74%
Net Income
$-55.4M
↑ 6.57%
Net Profit Margin
-18.2K%
↑ 207753.52%
Q2 FY24Q/Q Change
Revenue
$882.0K
↑ 190.13%
Net Income
$-67.4M
↑ 21.65%
Net Profit Margin
-7.6K%
↑ 10580.59%
Q3 FY24Q/Q Change
Revenue
$28.3M
↑ 3105.33%
Net Income
$-26.4M
↓ 60.75%
Net Profit Margin
-93.55%
↑ 7546.25%
FY18Y/Y Change
Profit
$-11.7M
↑ 58.13%
FY19Y/Y Change
Profit
$460.0K
↓ 103.95%
FY20Y/Y Change
Profit
$-49.8M
↓ 10925.87%
FY21Y/Y Change
Profit
$610.0K
↓ 101.22%
FY22Y/Y Change
Profit
$-272.0K
↓ 144.59%
FY23Y/Y Change
Profit
$-123.5M
↑ 45305.51%
Q2 FY23Q/Q Change
Profit
$-246.0K
↑ 6.96%
Q3 FY23Q/Q Change
Profit
$-29.3M
↑ 11795.12%
Q4 FY23Q/Q Change
Profit
$-218.0K
↓ 99.26%
Q1 FY24Q/Q Change
Profit
$29.0K
↓ 113.3%
Q2 FY24Q/Q Change
Profit
$436.0K
↑ 1403.45%
Q3 FY24Q/Q Change
Profit
$28.2M
↑ 6369.95%
FY18Y/Y Change
Operating Cash Flow
$-21.0M
↑ 2.2%
Investing Cash Flow
$-77.7M
↓ 438.35%
Financing Cash Flow
$93.0M
↑ 8267.96%
FY19Y/Y Change
Operating Cash Flow
$-43.8M
↑ 108.62%
Investing Cash Flow
$27.4M
↓ 135.26%
Financing Cash Flow
$19.5M
↓ 79.03%
FY20Y/Y Change
Operating Cash Flow
$-66.7M
↑ 52.07%
Investing Cash Flow
$-105.3M
↓ 484.38%
Financing Cash Flow
$168.3M
↑ 763.36%
FY21Y/Y Change
Operating Cash Flow
$-95.6M
↑ 43.37%
Investing Cash Flow
$71.9M
↓ 168.31%
Financing Cash Flow
$48.6M
↓ 71.16%
FY22Y/Y Change
Operating Cash Flow
$-127.4M
↑ 33.3%
Investing Cash Flow
$62.1M
↓ 13.73%
Financing Cash Flow
$87.3M
↑ 79.72%
Q2 FY23Q/Q Change
Operating Cash Flow
$-29.6M
↓ 36.16%
Investing Cash Flow
$-44.4M
↓ 75.13%
Financing Cash Flow
$18.3M
↓ 93.47%
Q3 FY23Q/Q Change
Operating Cash Flow
$-50.8M
↑ 71.75%
Investing Cash Flow
$-4.7M
↓ 89.39%
Financing Cash Flow
$29.4M
↑ 60.05%

Geron Technicals Summary

Sell

Neutral

Buy

Geron is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Geron Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Geron Corporation logo
-21.78%
-40.28%
51.27%
170.91%
105.52%
Biontech Se logo
-0.42%
31.01%
14.23%
-32.79%
252.68%
Regeneron Pharmaceuticals, Inc. logo
-1.1%
-34.53%
-23.52%
17.29%
85.93%
Vertex Pharmaceuticals Incorporated logo
-11.69%
-15.46%
-5.51%
78.89%
75.53%
Alnylam Pharmaceuticals, Inc. logo
5.85%
3.38%
37.75%
85.55%
116.42%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Geron Corporation logo
NA
NA
-2.38
-0.28
-0.69
-0.3
NA
0.49
Biontech Se logo
160.8
NA
0.04
-3.2
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
17.24
17.24
1.03
44.96
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.07
0.49
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Geron Corporation logo
Buy
$1.9B
105.52%
NA
0.0%
Biontech Se logo
Buy
$29.5B
252.68%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$76.6B
85.93%
17.24
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$105.5B
75.53%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$30.7B
116.42%
NA
-15.86%

Geron Dividend announcements

  • Geron Earnings

    Geron’s price-to-earnings ratio stands at None

    Read More

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Organization
Geron
Employees
141
CEO
Dr. John A. Scarlett M.D.
Industry
Health Technology

Management People of Geron

NameTitle
Dr. John A. Scarlett M.D.
Chairman of the Board, President & CEO
Ms. Michelle J. Robertson
Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
Dr. Andrew J. Grethlein Ph.D.
Executive VP & COO
Mr. Scott Samuels
Executive VP, Chief Legal Officer & Secretary
Ms. Aron Feingold
Vice President of Investor Relations & Corporate Communications
Ms. Shannon T. Odam
Senior VP & Chief People Officer
Ms. Melissa A. Kelly Behrs
Executive VP of Business Operations & Chief Alliance Officer
Mr. Edward E. Koval
Executive VP & Chief Business Officer
Dr. Faye Feller M.D.
Executive VP & Chief Medical Officer
Mr. James Ziegler M.B.A.
Executive VP & Chief Commercial Officer

Important FAQs about investing in Geron from India :

What is Geron share price today?

Geron share price today stands at $2.98, Open: $3.10 ; Previous Close: $3.17 ; High: $3.05 ; Low: $2.80 ; 52 Week High: $5.34 ; 52 Week Low: $1.64. The stock opens at $3.10, after a previous close of $3.17. The stock reached a daily high of $3.05 and a low of $2.80, with a 52-week high of $5.34 and a 52-week low of $1.64.

Can Indians buy Geron shares?

Yes, Indians can invest in the Geron (GERN) from India.

With INDmoney, you can buy Geron at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Geron at zero transaction cost.

How can I buy Geron shares from India?

It is very easy to buy Geron from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Geron be purchased?

Yes, you can buy fractional shares of Geron with INDmoney app.

What are the documents required to start investing in Geron stocks?

To start investing in Geron, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Geron

Today’s highest price of Geron (GERN) is $3.05.

Today’s lowest price of Geron (GERN) is $2.80.

What is today's market capitalisation of Geron

Today's market capitalisation of Geron GERN is 1.9B

What is the 52 Week High and Low Range of Geron

  • 52 Week High

    $5.34

  • 52 Week Low

    $1.64

What are the historical returns of Geron?

  • 1 Month Returns

    -21.78%

  • 3 Months Returns

    -40.28%

  • 1 Year Returns

    51.27%

  • 5 Years Returns

    105.52%

Who is the Chief Executive Officer (CEO) of Geron

Dr. John A. Scarlett M.D. is the current Chief Executive Officer (CEO) of Geron.